INTRODUCTION
Herpes simplex virus type 2 (HSV-2) is a primary cause of genital ulcers and is one of the most prevalent sexually transmitted infections worldwide 1 . Recent serological studies conducted among populations with no specific high-risk sexual behaviour characteristics in sub-Saharan Africa have shown prevalence rates that exceed those of similar populations in the USA and Europe 2 . Up to 70% of high-risk HIV-1 seronegative and up to 85% of HIV-1 seropositive persons are seropositive for HSV-2 in sub-Saharan Africa 2, 3 . However, sero-epidemiological studies of HSV-2 in Africa have been hampered by concerns that some of the newer HSV-2 ELISAs are associated with high rates of falsepositive reactions in African sera. In an evaluation study of thirteen HSV-2 type-specific assays, the specificity ranged from 47 to 99% 4 . In this evaluation, the HerpeSelect® (Focus Technologies) was shown to have a high sensitivity (100%) but a low specificity (71%), while the Kalon™ HSV-2 gG2 ELISA was one of the best performing tests (sensitivity 93% specificity 98%). Specificity was shown to be lower in HIV-1 seropositive individuals. In another study of sera from populations in South Africa, Zimbabwe, Kenya and Uganda using the HerpeSelect® 5 , 100% concordance with Western blot (WB) was observed in sera from Zimbabwe and South Africa, but was lower for samples from Kenya (96%) and Uganda (88%). More recently, a study comparing HerpeSelect® and Kalon TM with WB in 120 HIV-1 seronegative men aged 18-24 years in Kenya showed a lower specificity for HerpeSelect® (40%) compared to Kalon TM (79%) 6 . Another more recent study using 538 Ugandan samples tested with WB, two ELISA assays and a rapid test (Biokit   TM   ) confirmed the lower specificity of HerpeSelect® (51%) which was improved by raising the cut-off value for positive results to 3.2. In the same study, the specificity of the Kalon TM assay was found to be superior to HerpeSelect®; this was enhanced further by raising the cut-off for positive results to 1.5 which increased specificity from 88% to 92% 7 . This study did not find any significant difference in assay performance by HIV-1 serostatus.
While sensitive tests are more useful for diagnosis, higher levels of specificity are required in epidemiological studies where associations with other infections like HIV-1 are explored. Highly specific testing strategies are required to identify individuals who might benefit from HSV treatment interventions currently being evaluated in trials. Largescale WB testing is costly, and not feasible in many settings in Africa. For these reasons, were recorded as equivocal as per manufacturer's instructions.
Using a pre-determined sampling strategy, a random selection of specimens with concordant results and all discordant results (with serum remaining) were shipped to the University of Washington, Seattle, USA, for evaluation using a gold standard WB assay which has been previously described 11 .
Samples with remaining serum were tested for HIV-1 using Abbott AxSYM HIV 1/2 gO (Abbott Diagnostics, Wiesbaden-Delkenheim, Germany) in South Africa only when it became apparent that HIV-1 serostatus might influence HSV-2 ELISA results
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. Indeterminate results were resolved using BioRad
Genetic Systems rLAV HIV-1 ELISA (BioRad Laboratories, Redmond, USA).
The sensitivity and specificity of the different tests were calculated, taking into account the sampling strategy, according to methods described by Hawkins et al 12 .
Only samples with (normalised) OD readings >1.1 were considered positive. Additional analyses were performed to investigate whether sensitivity and/or specificity of the tests could be improved by changing the cut-off values for positive specimens using receiver operator characteristic (ROC) curves and likelihood ratios. We specifically investigated the sensitivity and specificity of a higher cut-off value for HerpeSelect® of ≥3.5 as has been suggested by other authors 5, 13 . The effect of age and HIV-1 serostatus on sensitivity and specificity were also explored. 
RESULTS

Population characteristics
Participants had a mean age of 25.6 years (range 18-46). The overall HSV-2 seroprevalence for this population varied by as much as 14%, depending on the test used. Of the 210 specimens tested, 168 (80%) of women were HSV-2 seropositive, 40
(19%) were negative, and 2 results (1%) were equivocal using HerpeSelect®. With the Kalon™ assay, 138 (66%) of the samples were HSV-2 seropositive, 58 (28%) were seronegative, and 14 (7%) results were equivocal. HIV-1 results were available for 145 (69%) participants. The overall HIV-1 prevalence was 52%.
The results of testing using HerpeSelect® and Kalon™ were compared. Of the 210 samples tested, 178 (85%) had concordant results for both tests: 138 (66%) were concordant positive, 42 (20%) were concordant negative and none were equivocal on both tests. Thirty-two specimens (15%) specimens had discordant results. In the samples with discordant results, the majority (n=30) were positive on HerpeSelect® but either negative (n=16) or equivocal (n=14) on Kalon™. In two cases, samples were equivocal on HerpeSelect® and negative with Kalon™. Overall, HerpeSelect® appeared to detect positive specimens more frequently than Kalon™ (see table 1 ). Because both HerpeSelect® and Kalon™ yield continuous results based on OD readings, it was possible to explore the sensitivity and specificity of the test depending on the cut-off value chosen to define a positive test. Initially, we examined the higher cut-off value for HerpeSelect® of ≥ 3.5, which has been proposed by others 13 . While this resulted in a decreased sensitivity (94%), the specificity was substantially improved (87%). Further exploration using ROC curves showed that 3.3 was the cut-off value for optimal sensitivity (96%) and specificity (87%), correctly classifying 86% of samples. For
Kalon™, further interpretation of the ROC curve suggested that there was nothing to be gained in terms of sensitivity by changing the cut-off above or below the recommended index of 1.1. We subsequently analysed whether using two ELISAs in combination improved sensitivity and specificity when compared to WB. The best combination was obtained when using HerpeSelect® at increased cut-off (>3.5) followed by testing of "low positive" and equivocal samples with Kalon™, yielding sensitivity of 92% (95%CI: 82-98) and specificity of 91% (95%CI: 79-98%). Using this approach 22 (10%) of the original samples tested by HerpeSelect would have required retesting with Kalon.
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Effect of age and HIV-1 serostatus on assay performance
In an exploratory analysis, we investigated the effect of age and HIV-1 serostatus on assay performance (see table 3 ). The sensitivity of both tests was lower in the age group <25 years compared to those in the age group ≥25 years. Conversely, specificity was higher for both tests in the <25 years age group, compared to the older age group. The sensitivity of HerpeSelect® in HIV-1 seropositive specimens was high (100%). By contrast, its specificity was substantially lower in specimens of participants co-infected with HIV-1 (30%), but was improved by raising the cut-off to ≥3.5 (80%). The performance of Kalon™ was broadly comparable (sensitivity 91%, specificity 72%). 
DISCUSSION
The sensitivity of HerpeSelect® and Kalon™ observed in this study is high and similar to previous observations from other African settings where both HSV and HIV-1 prevalence are high 4, 13, 14 , and compares favourably with the results from industrialised countries 15 .
We found a wide variation in specificity between the two tests, with HerpeSelect® demonstrating a high rate of false positive results, using the cut-off value recommended by the manufacturer. This resulted in an overestimation of seroprevalence in this population by as much as 14%. This is in contrast to observations by Hogrefe et al who found a specificity of 100% in sera from South Africa and Zimbabwe
5
, although this was similar to observations from other studies in Uganda, Kenya, Zambia, Benin and Nigeria, where specificity was as low as 40%-70% 4, 6, 7, 13 .
There are several possible explanations for the higher sensitivity but lower specificity of HerpeSelect® compared with Kalon. One explanation is that HerpeSelect® is more sensitive than Kalon™, and even WB, in detecting early seroconversion. A study comparing the median time to seroconversion of the three assays found that this was significantly longer for Kalon™ (120 days) and WB (87 days, p=0.004), than for HerpeSelect® (21 days, p<0.001) 16 . A recent study among African patients with genital ulcer disease also found that rates of HSV-2 seroconversion in cases of documented first episodes of genital HSV-2 were significantly higher by HerpeSelect® compared to Kalon™ (77% vs. 23% at Day 14)
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. The high HSV-2 prevalence in this population suggests that seroconversion is not a rare event. In addition, 50% of the HerpeSelect® false positive tests had readings in the low positive range, which may be suggestive of early infection 13 . However, for this to be true, we would have expected to observe higher false positive rate in the younger age group, compared to the older age group. This was Page 11 of 17 not the case in our study. In fact, we observed a lower sensitivity (of both assays) in the younger population compared to the older population.
An alternative explanation for the differences in specificity could be cross reactivity with other infections, including HSV-1 or HIV-1. While the glycoprotein-G2 tests are generally quite specific for HSV-2, one study found that, in patients with cultured-documented recurrent genital HSV-1 infection, the specificity of Kalon™ was 100%, whilst the specificity of HerpeSelect® was slightly lower (93%) 16 . Golden et al showed the impact of HSV-1 on lowering the specificity of HerpeSelect ® in male STD clients 18 . We were unable to test whether there was cross-reactivity with HSV-1 because of the high prevalence of HSV-1 (98% of samples tested by WB) in this population. Perhaps a more plausible explanation relates to the presence of circulating non-specific antibodies, which could either could be the result of hyperglobulinaemia secondary to immune activation caused by HIV-1, or even could be the antibodies to HIV-1 themselves, which might cross react with the G2-specific portion of the test 19, 20 . Specificity was also shown to be lower in HIV-1 seropositive samples in the analysis of samples from the Four African City However, HIV-1 prevalence was lower in this Ugandan population (33%) than in our South African population (52%). Higher rates of co-infection with HIV-1 in the older age groups may also explain the higher specificity observed in the younger age group in our study. While not conclusive, we also noted in our study that all HSV-2 false positive tests with available HIV-1 results were indeed HIV-1 positive.
A third possible explanation is geographical variation in HSV-2 strains. Although data from Europe suggest that the gG2 epitope is fairly well conserved 21 , strains from African populations have not been sequenced. These strains may be more diverse and have different affinities for both the ELISA assays, as well as the WB. Certainly, atypical WB profiles were observed in this study (data not shown), and have been reported by other investigators 5, 13 , 6 Raising the cut-off value for defining positive results for HerpeSelect® appeared to improve the specificity without compromising sensitivity too much and compares well with the Kalon™ assay. This approach was eventually used as the strategy for identifying participants with HSV-2 for inclusion in two large multi-centre HSV-2 suppressive treatment trials 22, 23 . We showed that the same approach did not yield similar improvements in performance for the Kalon™ assay. This may be because this test is already fairly specific for HSV-2 and further improvements in specificity result in losses in sensitivity.
Finally we showed that using a combination of two tests resulted in high levels of sensitivity and specificity being obtained when compared with WB. Using HerpeSelect® with a higher cut-off and testing all equivocal results with Kalon™ as the resolver test resulted in a testing algorithm which was suitably sensitive and specific, and only required re-testing of 10% of the original sample. Economic and operational research will be warranted to determine the role of these strategies in other settings. The demand for improved HSV-2 testing strategies is likely to grow with increasing awareness of the high prevalence of HSV-2 in the developing world, and its association with HIV-1 transmission.
In conclusion, high rates of false positivity continue to challenge the performance of the HerpeSelect® assay in African sera. In particular, the poor specificity of the test in HIV-1 seropositive populations warrants its cautionary use and a larger scale investigation.
However, adjusting the cut-off and/or using a two-test testing algorithm resulted in significant improvements when compared with using either test alone. The feasibility and cost-benefit of such approaches should be further evaluated.
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Key messages
• HSV-2 seroprevalence ranged from 66% with the Kalon TM ELISA to 80% with the HerpeSelect ® ELISA.
• HerpeSelect® had a high sensitivity but lower specificity while Kalon TM was less sensitive but more specific.
• HIV-1 infection appeared to reduce the specificity of HerpeSelect®.
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• Specificity was improved by raising the cut-off index for determination of a positive result for HerpeSelect® (to ≥3.5), but not for Kalon TM .
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